Keywords
Eligibility Determination ×
Leukemia ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

122 Search results.

Eligibility Leukemia NCT02188706

- 6/25/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT02188706

Eligibility Leukemia NCT02126553

- 6/25/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission; ODM derived from: https://clinicaltrials.gov/show/NCT02126553

Eligibility Leukemia NCT02193100

- 6/25/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center; ODM derived from: https://clinicaltrials.gov/show/NCT02193100

Eligibility Leukemia NCT02272777

- 6/25/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase; ODM derived from: https://clinicaltrials.gov/show/NCT02272777

Eligibility Leukemia NCT01893320

- 6/24/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01893320

Eligibility Leukemia NCT02096055

- 6/24/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT02096055

Eligibility Leukemia NCT02096042

- 6/24/20 - 1 form, 2 itemgroups, 24 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT02096042

Eligibility Leukemia NCT02028039

- 6/24/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT02028039

Eligibility Leukemia NCT01692197

- 6/23/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT01692197

Eligibility Leukemia NCT01786343

- 6/23/20 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01786343

Eligibility Leukemia NCT01664897

- 6/23/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pilot Phase II - Erlotinib for Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01664897

Eligibility Leukemia NCT01891981

- 6/23/20 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I/II Study of Moxetumomab; ODM derived from: https://clinicaltrials.gov/show/NCT01891981